|Day Low/High||53.76 / 55.27|
|52 Wk Low/High||36.15 / 57.44|
Across all sectors, stocks are rising in tandem with rates -- but I think this stupidity will end soon.
The shares have more moves than a shortstop batting .110. From bottom to high to bottom to high, AstraZeneca (AZN) has traversed about 9 points today. More moves than a shortstop batting .110.
I sold out of my AstraZenca long for a nice gain. I just sold out of the balance of my AstraZeneca (AZN) long rental at $72.30, a nice way to start the day.
Just collected some profits on my premarket AstraZeneca purchase. I just sold out more than half of my AstraZeneca (AZN) long rental at $71.90, for more than a $1.20-per-share gain.
Maybe the rally has simply been too soon and too fast. There was little in the way of weekend news that would lead one to expect a down futures opening. So, maybe the rally has simply been too soon and too fast. There was some dovish news on Bernank...
In an effort to smooth approval for its $106 billion merger, Pfizer and AstraZeneca are set to meet UK regulators on Tuesday who are wary a deal will lead to British job cuts.
The biggest overvaluation is the undervaluation of risk in that market.
These two structural issues go a long way toward explaining this sluggish growth.
LinkedIn is among loss leaders on the tech scene in 2014, and its earnings report Thursday did little to improve investors' outlook.
Pharma giant Pfizer revealed Monday it made a $99 billion bid for AstraZeneca in January and had contacted its rival again on April 26 about a takeover.
Suddenly these companies have gone from embarrassing to, yes, embarrassingly rich.
That was quick. I have covered my AstraZeneca (AZN) short for a quick profit.
I doubt this story. A London Sunday Times article suggests that Pfizer (PFE) considered acquiring AstraZeneca (AZN), but the talks stalled and will not resume. I am doubtful of this story and I have shorted AZN, +$6 in premarket trading as the compa...
Array is partnering with AstraZeneca and Novartis on a number of cancer drugs with trials soon getting underway that could transform the company by year end.
James Molloy, Managing Director at Janney Montgomery Scott explains why Actavis buying Forest Labs is a smart for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.
The U.K.'s AstraZeneca and Germany's Bayer spend up to a combined $7.2 billion shoring up their portfolios. Laura Board reports from London.
Credit rating agency Standard & Poor's upgrades its credit outlook for the U.S. government to Stable from Negative.
Merger Monday begins with AstraZeneca buying Pearl, while Apple could announce iRadio and Google may purchase Waze as futures look up.
Stocks are up as AstraZeneca pays millions for Omthera, while Valeant buys Bausch & Lomb and Tiffany's earnings shine.
Hewlett-Packard announces a 10% increase in its quarterly dividend. Brittany Umar has details on that as well as a look at the day's other most searched trends on the Web.
LifeLock looks to be the best offering for the IPOs planned on Wednesday according to IPO Desltop President Francis Gaskins.
These companies are performing like champions, despite a weak British economy.
Stephanie Link, director of research at TheStreet, eliminated her position in Abbott to build a position in Bristol Meyers.
A look at some of the day's most searched topics on the Web, includingApple as the company shells out $60 million to settle its iPad namingdispute with Proview Technology.
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.